ERBB2 and head and neck cancer: Although a different disease context, a CPS cutoff of ≥10 is also a clinically meaningful predictor of response to pembrolizumab therapy in the setting of metastatic HER2 negative gastroesophageal squamous cell carcinoma and adenocarcinoma as seen in KEYNOTE-859; this may highlight CPS ≥10 as a potentially meaningful across different malignancies and nominates this group for further study within head and neck cancer (13).